Cargando…

The therapeutic effect of KSP inhibitors in preclinical models of cholangiocarcinoma

Cholangiocarcinoma (CCA) is an epithelial malignancy with a dismal prognosis owing to limited treatment options. Here, we identified several compound candidates against CCA using a high-throughput drug screen with approved or emerging oncology drugs, among which kinesin spindle protein (KSP) inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Yuanyuan, Cui, Xiaowen, Jiang, Tianyi, Pan, Yufei, Lin, Yunkai, Feng, Xiaofan, Ding, Zhiwen, Yang, Chun, Tan, Yexiong, Wang, Hongyang, Dong, Liwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485230/ https://www.ncbi.nlm.nih.gov/pubmed/36123339 http://dx.doi.org/10.1038/s41419-022-05247-0

Ejemplares similares

Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma
por: Shang, Taiyu, et al.
Publicado: (2023)

URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers
por: Ding, Zhiwen, et al.
Publicado: (2023)

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells
por: Kim, Ki Hyung, et al.
Publicado: (2009)

Expression of Ksp-cadherin during kidney development and in renal cell carcinoma
por: Thedieck, C, et al.
Publicado: (2005)

KSP: an integrated method for predicting catalyzing kinases of phosphorylation sites in proteins
por: Ma, Hongli, et al.
Publicado: (2020)

KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway
por: Song, In-Sung, et al.
Publicado: (2015)

KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL
por: Zhu, Li, et al.
Publicado: (2016)

POLD2 and KSP37 (FGFBP2) Correlate Strongly with Histology, Stage and Outcome in Ovarian Carcinomas
por: Elgaaen, Bente Vilming, et al.
Publicado: (2010)

Correction: POLD2 and KSP37 (FGFBP2) Correlate Strongly with Histology, Stage and Outcome in Ovarian Carcinomas
por: Elgaaen, Bente Vilming, et al.
Publicado: (2010)

Simultaneous silencing of VEGF and KSP by siRNA cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells
por: Doan, Chung Chinh, et al.
Publicado: (2014)

Ksp1-dependent phosphorylation of eIF4G modulates post-transcriptional regulation of specific mRNAs under glucose deprivation conditions
por: Chang, Yeonji, et al.
Publicado: (2018)

RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding
por: Feng, Xiaofan, et al.
Publicado: (2021)

Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma
por: Lu, Xinjun, et al.
Publicado: (2023)

CD133/Prominin-1-Mediated Autophagy and Glucose Uptake Beneficial for Hepatoma Cell Survival
por: Chen, Haiyang, et al.
Publicado: (2013)

Reappraisal of the Therapeutic Role of Celecoxib in Cholangiocarcinoma
por: Yeh, Chun-Nan, et al.
Publicado: (2013)

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma()()()
por: Zakharia, Kais, et al.
Publicado: (2018)

Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma
por: Wang, Qingqing, et al.
Publicado: (2022)

Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells
por: Kim, Do Hyung, et al.
Publicado: (2013)

The role and implication of autophagy in cholangiocarcinoma
por: Khizar, Hayat, et al.
Publicado: (2023)

A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression
por: Chen, Haiyang, et al.
Publicado: (2015)

Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
por: Dong, Mingjie, et al.
Publicado: (2018)

Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2022)

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
por: Serra-Camprubí, Queralt, et al.
Publicado: (2023)

Metabolic Reprogramming and Risk Stratification of Hepatocellular Carcinoma Studied by Using Gas Chromatography–Mass Spectrometry-Based Metabolomics
por: Fang, Chengnan, et al.
Publicado: (2022)

Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma
por: Perez-Montoyo, Hector
Publicado: (2020)

Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models
por: Zheng, Qingfan, et al.
Publicado: (2022)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development
por: Gu, Qingyang, et al.
Publicado: (2015)

Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma
por: Wu, Yanhua, et al.
Publicado: (2022)

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
por: Churi, Chaitanya R., et al.
Publicado: (2014)

Unveiling resistance mechanisms to EGFR inhibitors in cholangiocarcinoma
por: Vaquero, Javier, et al.
Publicado: (2018)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma
por: Zeng, Fan-li, et al.
Publicado: (2021)

Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2020)

Corrigendum: Long non-coding RNAs as molecular biomarkers in cholangiocarcinoma
por: Wu, Yanhua, et al.
Publicado: (2022)

Cold-Atmospheric Plasma Induces Tumor Cell Death in Preclinical In Vivo and In Vitro Models of Human Cholangiocarcinoma
por: Vaquero, Javier, et al.
Publicado: (2020)

Preclinical studies of toxicity and anti-cholangiocarcinoma activity of the standardized capsule formulation of Atractylodes lancea (Thunb.) DC
por: Plengsuriyakarn, Tullayakorn, et al.
Publicado: (2023)

Development of potent antibody drug conjugates against ICAM1(+) cancer cells in preclinical models of cholangiocarcinoma
por: Zhu, Bing, et al.
Publicado: (2023)

Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma
por: Chen, Ming-Huang, et al.
Publicado: (2015)

Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience
por: Wang, Longrong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_isehp4ud8gnlrtvvflce5hi5nn